Haematopoietic reconstitution after autologous stem cell transplantation (ASCT) was evaluated at different times in 26 lymphoma patients. All of the patients showed a significant decrease in the number of both committed (CFU-C) and more primitive progenitor cells (LTC-IC). The expansion of bone marrow progenitor cells in a 'stroma-free' long-term liquid culture system supplemented with SCF, IL-3, IL-6 and GM-CSF from 19 transplanted patients was significantly reduced compared to normal controls. The stromal cell compartment, evaluated by means of a CFU-F assay, was also greatly reduced. The number of haematopoietic and stromal cell progenitors was, nevertheless, very similar to their pre-transplant values. Bone marrow histology, which was evaluated at different times after transplant, showed an increase in reticulin fibres, the dilatation of parenchymal sinusoids and some morphological evidence of trilineage dysplasia in 11 patients; however, the same abnormalities were seen in the majority of pretransplant samples. No cytogenetic abnormalities were observed in 15 patients before transplant, but four subsequently developed persistent clonal karyotypic alterations and five showed non-clonal abnormalities that generally disappeared over time. Our data suggest that both the stromal and the haematopoietic compartments are somehow damaged after ASCT for lymphoma; however, these defects generally pre-exist the transplant conditioning regimen and seem to become less pronounced over time. Keywords: bone marrow transplantation; cytogenetics; haematopoietic stem cells; stromal cells High-dose chemo-radiotherapy followed by the infusion of cryo-preserved autologous bone marrow or peripheral blood stem cells has been increasingly used for the treatment of a variety of malignant haematopoietic diseases.
abnormalities have been described in both the haematopoietic and stromal cell compartments. A large number of authors have found a decrease in colony-forming unit (CFU-C) levels in both allogeneic and autologous bone marrow recipients (ABMT) a long time after transplant (up to 8.5 years). 4 ,5 Domenech et al 6 found an impairment in the long-term cultures of 33 patients after autologous bone marrow transplantation: the defect involved both CFU-C output and stromal cell formation. Using different techniques, van den Berg et al 7 and O'Flaherty et al 8 clearly demonstrated that a stromal cell compartment defect is always present after allogeneic bone marrow transplantation. More recently, Novitzky and Mohamed 9 have developed a modified CFU-Bl assay in which blastic colonies are grown for 5 weeks on a stromal layer (thus making it possible to evaluate the interaction between early progenitor and stromal cells); this clearly demonstrated a defect in stromal cell support for the growth of primitive clonogenic cells in 15 patients transplanted with both allogeneic and autologous grafts.
In an attempt to elucidate the nature and entity of the abnormalities observed after stem cell transplantation, we evaluated 26 patients at different time intervals. All of these were malignant lymphoma patients who had been autografted after being treated with the same conditioning regimen. The patients were all studied using an array of assays to evaluate the haematopoietic and stromal compartments both before and after stem cell transplant. We conclude that both compartments are indeed defective, although the majority of the abnormalities generally pre-exist the transplant conditioning regimen.
Patients and methods
Twenty-six patients affected by lymphoid malignancies, 17 with non-Hodgkin's lymphoma (NHL) and nine with Hodgkin's lymphoma (HD) were evaluated by means of various assays after stem cell transplantation. The majority were heavily pre-treated patients in second remission (the mean number of pre-transplant chemotherapy cycles was 9 Ϯ 3). None of the patients showed any immunophenotypic, histological or karyotypic signs of disease at the time of harvesting or after the transplant. All of the patients received the same pre-transplant conditioning regimen, consisting of VP-16 60 mg/kg, CTX 120 mg/kg and total body irradiation (10 Gy in 3 fractions). Thirteen patients received cryopreserved autologous bone marrow and 13 were engrafted with peripheral blood stem cells (PBSC) mobilised with CTX (1.5 g/m 2 ) and G-CSF (10 g/kg).
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The normal controls were 12 allogeneic bone marrow donors. The study was approved by the hospital's Ethics Commitee.
Sample preparation
The human bone marrow and peripheral blood samples were layered on a Ficoll-Paque gradient (specific gravity 1.077 g/ml; Nycomed Pharma, Oslo, Norway); the low density mononuclear cells (LD-MNC) were washed twice in Hanks' balanced salt solution (HBSS) and resuspended in Iscove's modified Dulbecco's medium (IMDM) with 10% fetal bovine serum (FBS).
Clonogenic assays
The CFU-GM and BFU-E assays were carried out in the 26 patients 1-10 months after transplant, and subsequently at 10-24 months and after 24 months; CFU-C were also assayed prior to the bone marrow or peripheral blood stem cell harvest in 15 patients. 1 ϫ 10 5 LD-MNC were plated in 35 mm Petri dishes in 1 ml of methylcellulose culture medium (MethoCult H4230; Stem Cells, Vancouver, Canada), containing 0.9% methylcellulose, 30% pretested FBS, 1% pretested BSA, 10 Ϫ4 m 2-mercaptoethanol with the addition of 15% 5637 cell line supernatant and 3 U/ml of human urinary erythropoietin. Triplicate dishes were incubated at 37°C with 5% CO 2 , in a fully humidified atmosphere for 14 days. Aggregates of у40 and of Ͻ40 cells were respectively scored as colonies and clusters, and counted after 14 days of culture.
Long-term culture initiating cells limiting dilution assay (LTC-IC LDA)
The frequency of LTC-IC was evaluated using a limiting dilution assay (LDA) in the LD-MNCs of 13 patients 1-10 months after transplant, and subsequently in a smaller number of patients after 10-24 months and more than 24 months; the number of LTC-IC was also evaluated prior to harvest in six patients. The LD-MNCs were seeded on the M2-10B4 murine cell line (1 ϫ 10 4 M2-10B4 irradiated (80 Gy) cells per well) in 96-well microtitre plates. The dilution steps (16 replicates for each dilution) were 6000, 12 000, 18 000, 24 000 and 30 000 cells/well in 200 l/well of LTBMC medium. After 5 weeks of culture at 33°C with 5% CO 2 , the adherent and non-adherent cells were harvested from each well by removing the medium and adding 50 l of trypsin per well for 10 min at 37°C. The trypsinized cells were washed from the wells using 50 l of FBS, and pooled with the non-adherent cells. In order to evaluate colony formation, the cells from each well were plated in 24-well plates in 250 l of semisolid medium for colony assay (MethoCult H4230), containing 0.9% methylcellulose, 30% pretested FBS, 1% pretested BSA, 10 Ϫ4 m 2-mercaptoethanol, with the addition of 15% 5637 cell line supernatant and 3 U/ml of human urinary erythropoietin, and incubated at 37°C with 5% CO 2 in a fully humidified atmosphere for 14 days. The incidence of negative wells was then determined and the frequency of LTC-IC evaluated by means of Poisson statistics.
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Stroma-free liquid cultures
Stroma-free liquid cultures were established by seeding the LD-MNCs from 19 patients at different times after the transplant: 6.5 ϫ 10 5 cells/ml were seeded in 25 cm 2 tissue culture flasks in IMDM supplemented with 10% FBS, and then incubated at 37°C in a fully humidified atmosphere with 5% CO 2 in air for 4 weeks. On day 0, and then every 48 h for 4 weeks, the cultures were fed with a combination of cytokines, including 50 ng/ml of recombinant human stem cell factor (rhuSCF) (Amgen, Thousand Oaks, CA, USA), 100 ng/ml of recombinant human granulocytemacrophage colony-stimulating factor (rhuGM-CSF) (Sandoz, Basel, Switzerland), 100 ng/ml of recombinant human interleukin 3 (rhuIL-3) (Sandoz) and 10 ng/ml of recombinant human interleukin 6 (rhuIL-6) (Pharmacia, Milan, Italy). At weekly intervals, the cultures were demipopulated by removing half of the culture volume, which was replaced with fresh medium and cytokines. The cells collected from the refeed were counted, assessed for viability by means of trypan blue dye exclusion, and tested for progenitor cells using clonogenic assays. The CFU-GMfold increase (CFU-GM FI) was calculated by dividing the absolute number of CFU-GM at each time point during the culture (CFU-GM incidence multiplied by the increase in the number of living nucleated cells) by their absolute number at time 0.
CFU-F assay
CFU-F were assayed in 17 patients soon after transplant (1-10 months) and at subsequent intervals; a small cohort of patients (six patients) were also evaluated before stem cell harvest.
The LD-MNCs were resuspended in Iscove's modified Dulbecco's medium with 20% FBS at a final concentration of 1 ϫ 10 6 cells/25 cm 2 flask. The cultures were then incubated in a humidified atmosphere with 5% CO 2 at 37°C for 5 days. During the fifth day of culture, all of the medium and non-adherent cells were removed and replaced by fresh medium. The cultures were ended after 9 days. For scoring the fibroblast colonies, the flasks were washed twice with PBS and the cells fixed with methanol and stained with crystal violet. 13, 14 Bone marrow histology Serial bone marrow trephine biopsies were analysed before harvesting and 1, 12 and 24 months after stem cell transplantation.
The samples were fixed for 4-18 h in 10% buffered formalin or Bouin's solution, decalcified overnight in nitric acid, and embedded in paraffin. Sections of 2-4 m were mounted on 2% 3-(triethoxylsilyl) propylamine-treated coverslips (Merck, Darmstadt, Germany). Bone marrow cellularity was visually assessed according to Frisch et al 15 and then classified as normal (20-50 vol%), decreased (Ͻ20%) or increased (Ͼ50%). Bone marrow fibrosis was evaluated after reticulum silver staining 16 and graded from 0 to 4 according to Manoharan et al. 17 
Cytogenetic analysis
A larger cohort of patients (19 LNH and 12 HD) was analysed for cytogenetics at different time intervals. A single karyotype analysis was made in only seven patients, whereas 24 patients underwent two or more determinations after transplant. A cytogenetic analysis was also performed prior to harvest in 15 patients. Chromosome examinations were performed on bone marrow aspirates after 24-48 h of culture without mitogens, and prepared for metaphase analysis by means of Q-banding. An average number of 25 mitoses was analysed for each test, and the karyotypes were described according to the standard international nomenclature. 18 A chromosomally abnormal clone was defined as two or more cells with the same additional chromosome or structural chromosome abnormality, or as three or more cells with the same missing chromosome. Abnormalities in fewer cells than those defined above were considered non-clonal.
Statistical analysis
The number of colonies and the stroma-free expansion values were compared at different time intervals, in normal and in pre-transplant (pre-harvest) controls using the Mann-Whitney test for independent groups.
Results
Results of the colony-forming assays are shown in Figure 1 .
The mean number of BFU-E was 29 Ϯ 14 at 1-10 months after transplant, 34 Ϯ 28 at 10-24 months and 38 Ϯ 17 after more than 24 months; the mean number of CFU-GM was 33 Ϯ 20, 36 Ϯ 28 and 42 Ϯ 22 at the same time intervals: these values were significantly less than those observed in the normal controls (P Ͻ 0.01). This defect does not seem to improve over time, as can be seen from the assays made 2 years after transplant. However, there were no significant differences in clonogenicity in comparison with the pre-transplant samples (BFU-E = 38 Ϯ 20 and CFU-GM = 49 Ϯ 67).
The frequency of progenitor cells, which was evaluated by means of the LTC-IC assay, was greatly reduced at the different time intervals (Figure 2 ): the number of LTC-IC was 8.1 Ϯ 8 per 1 ϫ 10 6 LD-MNCs before harvest, 16 Ϯ 12 at 1-10 months after transplant, 6.1 Ϯ 6 at 10-24 months and 5.8 Ϯ 5 at more than 2 years: these values did not differ statistically from each other, but were significantly lower than those observed in normal controls (LTC-IC in 12 normal subjects 59 Ϯ 31 colonies per 1 ϫ 10 6 of seeded LD-MNCs).
Stroma-free, cytokine-driven liquid cultures were performed for 19 patients at different time intervals after transplantation (Figure 3) . In all but two cases, no expansion of CFU-GM was observed during the 4 weeks of culture, and the cultures rapidly converted to macrophages; no apparent improvement in the expansion capability of myeloid cells was observed even in patients transplanted some years before. The expansion defect in liquid cultures was less prominent prior to transplantation.
As detected by the CFU-F assay, bone marrow stromal cell precursors were also very deficient at all times after transplantation ( Figure 4 ). In particular, the mean CFU-F values were 1.6 Ϯ 3 per 1 ϫ 10 6 LD-MNCs seeded at 1-10 months after the transplant, and 1.3 Ϯ 2 at 10-24 months (when our normal control values were 14 Ϯ 3.7 CFU-F per 1 ϫ 10 6 LD-MNCs). The CFU-F number was slightly higher in a small cohort of patients studied before transplant (4.1 Ϯ 4); furthermore, CFU-F seemed to recover over time in nine patients evaluated more than 2 years after the transplant (CFU-F = 5.5 Ϯ 5 per 1 ϫ 10 6 LD-MNCs); however, these differences were not statistically significant, probably because of the small sample size.
The patients serially evaluated by means of bone marrow biopsy at 1, 12 and 24 months after transplantation showed slightly decreased cellularity, some degree of reticulum fibrosis, the presence of sinusoidal edema and frequently dysplastic changes involving one or more haematopoietic lineages (Table 1) . Surprisingly, when the bone marrow of patients re-staged prior to stem cell harvesting and transplantation were re-examined, a significant number of biopsies showed dysplastic changes, two of them being multi-lineage: these abnormalities were still present 1, 12 and 24 months after transplantation in one patient and at 24 months in a second patient; one patient with dysplastic changes in the erythroid lineage before transplant developed clear-cut myelodysplasia 6 months after transplantation, which rapidly evolved into acute leukaemia; in the other patients (with abnormalities of one or two lineages), progressive improvement was observed after transplant.
A slightly larger cohort of patients (31 patients)
30 (49) 39 (32) 1 (25) 2 (25) 3 (24) 31 (18) 6 (16) 7 (15) 8 (14) 10 (12) 11 (12) 18 (10) 12 (6) 13 (6) 19 (5) 29 (3) 23 (1) 34 (1) 35 ( underwent serial cytogenetic analysis at different time intervals after transplant. Four patients (13%) developed clonal cytogenetic abnormalities, two of whom had the morphological features of a myelodysplastic syndrome (Table 2) . Five patients showed non-clonal chromosomal abnormalities (16%): the fraction of abnormal cells was a minority in all cases, highly variable at the different times of analysis, and had a general tendency to disappear over time. Twenty-two patients (71%) showed a persistent normal karyotype. In the 15 patients, in whom karyotypic analysis was performed before transplantation (generally prior to harvest), no evidence of clonal or non-clonal abnormalities was ever found.
Discussion
The results of this study demonstrate that patients undergoing ASCT show defective haematopoiesis that involves both the stem cell and stromal cell compartments.
The presence of a reduced number of committed progenitor cells despite normal peripheral blood cell counts has been described after both allogeneic 4, 19, 20 and autologous bone marrow transplantation. 5, 6, 21 It is already well known that there is a correlation between the number of cycles of radio/chemotherapy and depletion of the stem cell compartment. 1 On the other hand, the reports of reversible changes after transplantation 20 have all been observed in patients transplanted with allogeneic bone marrow for acute leukaemia and aplastic anemia (in both cases with relatively short courses of chemotherapy). However, when comparing our CFU-C and LTC-IC data with pre-transplant values, it was evident that the haematopoietic pool was already defective before transplant, possibly because of irreversible damage to the haematopoietic cells in our heavily pretreated patients.
A defective stromal cell compartment, evaluated by means of CFU-F assay and the morphological analysis of bone marrow biopsies, was also observed after transplant; once again these defects were also present before stem cell harvest.
The only in vitro assay in which some differences between pre-and post-transplantation values were seen was our cytokine-driven stroma-free liquid culture, 22, 23 which revealed almost no expansion capabilities in the majority of the transplanted patients but some expansion capabilities in the pre-transplant samples. These data, which are somewhat difficult to explain, seem to indicate a proliferative defect of committed progenitor cells, since the CFU-GMfold expansion data relate to the CFU-GM number in the initial inoculum. The qualitative defect revealed in this culture system may depend on a defective growth factor response 24 and be a stroma-independent phenomenon. 8 These data indicate that the clonal capabilities of precursor cells are depressed after ASCT, but give little information on early precursors. These cells might be qualitatively (as seen in the CFU-Bl-stromal assay 9 ) or quantitatively defective; LTC-IC might be under-estimated in the presence of a CFU-C defect and, in any case, probably do not represent the most primitive cells, which are now more precisely assessed by means of other assays such as the extended long-term culture initiating cell (E-LTC-IC) 25 or competitive repopulating unit (CRU) assays. 26, 27 The possibility that the early precursor pool is preserved after transplant could only be demonstrated with these assays for very early stem cells.
A qualitative defect in progenitor cells is also indicated by the presence of clonal and non-clonal karyotypic abnormalities in a percentage of our patients after ASCT; these defects, which have an incidence of 9/31 in our homogeneous series and do not seem to have any impact on prognosis, are very rare in normal bone marrow 28 and were never seen in any of the cases examined before harvesting. A qualitative defect in haematopoietic cells could derive from the freezing process, 29 the pre-transplant conditioning regimen (especially when including TBI) 30 or from the process of outgrowth in a damaged micro-environment. Clonal and non-clonal bone marrow karyotypic abnormalities have been described after autologous bone marrow transplantation for leukaemia 31 and lymphoma. 32 In all four of our patients with clonal abnormalities, these persisted over time, whereas the non-clonal abnormalities remained stable or showed a tendency to regress.
Taken together, these data seem to indicate that the haematopoietic and stromal cell compartments are reduced, but the relative contribution of a short-course conditioning regimen may only be proportionally cumulative with previous chemotherapeutic regimens. In the first months after ASCT, an already reduced stem cell pool is attempting to build up stable and long-lasting haematopoiesis in the presence of quantitatively and qualitatively abnormal bone marrow stroma: indicators of this 'stressed' haematopoiesis may be a poor response of committed progenitor cells to growth factors in liquid culture and the observed non-clonal karyotypic abnormalities. These non-clonal abnormalities tend to disappear with time and do not seem to indicate a possible evolution towards pre-leukaemic transformation. On the other hand, we confirm that clonal karyotypic abnormalities in post-transplant patients are frequent, persistent and generally lead to clear-cut myelodysplastic syndromes. These data are similar to those reported by other authors, who have indicated a high incidence of MDS after transplant. 3, [32] [33] [34] Although the significance of cytogenetic abnormalities is clearly established in this group of patients, morphological signs of dysplasia are more variable, tend to be present before transplant, and do not seem to be a good indicator of bone marrow damage after transplant.
